Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTONASDAQ:AVRONASDAQ:EIGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsAVROAVROBIO$9.98$0.88▼$1.65$62.85M1.23269,831 shs206,800 shsEIGREiger BioPharmaceuticals$4.35$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%-68.90%-95.37%AVROAVROBIO0.00%0.00%0.00%0.00%-90.51%EIGREiger BioPharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences1.2629 of 5 stars3.70.00.00.01.80.00.0AVROAVROBION/AN/AN/AN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences 3.33Buy$93.00∞ UpsideAVROAVROBIO 0.00N/AN/AN/AEIGREiger BioPharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APTO, AVRO, and EIGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $6.002/27/2025APTOAptose BiosciencesAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/12/2025APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AAVROAVROBION/AN/AN/AN/A$2.13 per shareN/AEIGREiger BioPharmaceuticals$15.77M0.00N/AN/A$37.68 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%5/12/2025 (Estimated)AVROAVROBIO$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/AEIGREiger BioPharmaceuticals-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A1.051.05AVROAVROBION/A26.1726.17EIGREiger BioPharmaceuticalsN/A3.313.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%AVROAVROBIO62.63%EIGREiger BioPharmaceuticals62.46%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences1.33%AVROAVROBIO9.20%EIGREiger BioPharmaceuticals4.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataAVROAVROBIO1344.89 million40.76 millionOptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableAPTO, AVRO, and EIGR HeadlinesRecent News About These CompaniesNew Route On Eiger's North Face Will Have to WaitApril 16, 2025 | msn.comRigiTech Eiger is reaching SAIL III, opening new horizons for drone logisticsApril 10, 2025 | suasnews.comEiger hosts Gelato Masterclass in Sri LankaMarch 28, 2025 | dailymirror.lkRemembering John Harlin, Eiger LegendMarch 23, 2025 | msn.comEiger TrailNovember 2, 2024 | myswitzerland.comThe role of lactate in the exercise-induced human growth hormone response: evidence from McArdle diseaseOctober 30, 2024 | bjsm.bmj.comEiger BioPharmaceuticals Inc (OTC:EIGRQ) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comClimbing the iconic Eiger mountain in SwitzerlandOctober 4, 2024 | swissinfo.chEiger Biopharmaceuticals Inc (EIGRQ)September 29, 2024 | investing.comMassive Rockfall on the North Face of the EigerSeptember 8, 2024 | yahoo.comFormer NFL Player Mark Pattison Tackles The EigerSeptember 2, 2024 | si.comEiger BioPharmaceuticals gets grant for combination treatment for hepatitis delta virus (hdv) infectionAugust 24, 2024 | pharmaceutical-technology.comEiger BioPharmaceuticals, Inc. (EIGRQ)August 13, 2024 | finance.yahoo.com72C.SG,0P00015QPW,0 (72C.SG)August 3, 2024 | ca.finance.yahoo.comSKYY Network and MedLife Use Eiger Drones to Transport STD Tests Collected at Electric Castle, Providing Same-Day Results Directly in the AppJuly 29, 2024 | suasnews.comPolkadot Welcomes Move: Eiger Completes Integration for Substrate Blockchains.July 26, 2024 | crypto-news-flash.comSSG Advises Eiger BioPharmaceuticals in Sale of Avexitide Program Assets to Amylyx PharmaceuticalsJuly 19, 2024 | abladvisor.comSentynl acquires Eiger’s Zokinvy for progeria treatmentMay 6, 2024 | pharmaceutical-technology.comSentynl, a Zydus Group company acquires Zokinvy to treat Hutchinson-Gilford progeria syndrome from Eiger BioPharmaMay 6, 2024 | pharmabiz.comNews - Eiger BioPharmaceuticalsMay 5, 2024 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPTO, AVRO, and EIGR Company DescriptionsAptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.AVROBIO NASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Eiger BioPharmaceuticals NASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
